Significant Improvement in Disability Scores Observed in Multiple Sclerosis ... - MarketWatch (press release)

[**Significant Improvement in **Disability** Scores Observed in Multiple Sclerosis **...****][1]
**MarketWatch (press release)**
Accumulation of **disability** was significantly slowed in patients with multiple sclerosis (MS) who were treated with alemtuzumab versus Rebif(R) (high dose subcutaneous interferon beta-1a), as measured by the Expanded **Disability** Status Scale (EDSS), **...**
[New Data on Genzyme MS Drug Shows Improvement in **Disability**][2]Xconomy
[Genzyme reports additional data from Phase III CARE-MS II trial][3]RTT News

[**all 5 news articles »**][4]

[1]: http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGH0MJ92AZcYtU2iGgWgzlrKld8Nw&url=http://www.marketwatch.com/story/significant-improvement-in-disability-scores-observed-in-multiple-sclerosis-patients-who-received-lemtradatm-alemtuzumab-compared-with-rebifr-in-phase-iii-trial-2012-04-24
[2]: http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEcGE1hPMmy5Fkxa1OZIZNI9zDJ4w&url=http://www.xconomy.com/boston/2012/04/24/new-data-on-genzyme-ms-drug-shows-improvement-in-disability/
[3]: http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEi-Q1jUQOn-rHcNJgJp32yxwSlMA&url=http://www.rttnews.com/1866972/genzyme-reports-additional-data-from-phase-iii-care-ms-ii-trial.aspx?type%3Dqf%26utm_source%3Dgoogle%26utm_campaign%3Dsitemap
[4]: http://news.google.com/news/more?gl=us&pz=1&ned=us&ncl=d85OJ0mUQLhAxwMTjxtCv7sOTfkbM

URL: http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGH0MJ92AZcYtU2iGgWgzlrKld8Nw&url=http://www.marketwatch.com/story/significant-improvement-in-disability-scores-observed-in-multiple-sclerosis-patients-who-received-lemtradatm-alemtuzumab-compared-with-rebifr-in-phase-iii-trial-2012-04-24